WCN26-3169 Tailored mRNA-1273 Booster Strategies Improve Vaccine Response in ESKD Following ChAdOx1 nCoV-19

Read full text Summarise with VIRAT
Authors: Kai‐Ting Chang, You-Hsien Lin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Although the global emergency phase of COVID-19 has subsided, optimizing vaccination strategies for immunocompromised populations remains a public health priority. Patients with end-stage kidney disease (ESKD) are known to have impaired immune responses. This study evaluated and compared humoral immune responses following booster vaccination with full- versus half-dose mRNA-1273 in ESKD and non-dialysis cohorts primed with ChAdOx1 nCoV-19.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies Vaccine Coverage and Hesitancy

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104556–104556
Publication date
25 March 2026
Language
EN